Development of an experimentally useful model of acute myocardial infarction: 2/3 nephrectomized triple nitric oxide synthases-deficient mouse

Journal of Molecular and Cellular Cardiology

Volumn 77, Issue , 2014, Pages 29-41

  Uchida, Taro ^a   Furuno, Yumi ^b   Tanimoto, Akihide ^c   Toyohira, Yumiko ^b   Arakaki, Kumiko ^a   Kina Tanada, Mika ^a   Kubota, Haruaki ^a   Sakanashi, Mayuko ^a   Matsuzaki, Toshihiro ^a   Noguchi, Katsuhiko ^a   Nakasone, Junko ^a   Igarashi, Tomonori ^b   Ueno, Susumu ^b   Matsushita, Masayuki ^a   Ishiuchi, Shogo ^a   Masuzaki, Hiroaki ^a   Ohya, Yusuke ^a   Yanagihara, Nobuyuki ^b   Shimokawa, Hiroaki ^d   Otsuji, Yutaka ^b   Tamura, Masahito ^b   Tsutsui, Masato ^a   more..

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute myocardial infarction; Arteriosclerosis; Nitric oxide synthase; Sudden cardiac death

Indexed keywords

8 ISOPROSTANE; AMLODIPINE; ANGIOTENSIN II; CREATININE; HYDRALAZINE; IRBESARTAN; NITRIC OXIDE SYNTHASE; STROMAL CELL DERIVED FACTOR 1ALPHA;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED VASCULAR SMOOTH MUSCLE CELL PROGENITOR CELL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CREATININE BLOOD LEVEL; ECG ABNORMALITY; HEART RATE VARIABILITY; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; KIDNEY DYSFUNCTION; MALE; MONOTHERAPY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PARTIAL NEPHRECTOMY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ST SEGMENT ELEVATION; STEM CELL; SUDDEN CARDIAC DEATH; SURVIVAL RATE; UPREGULATION; ANIMAL; DISEASE MODEL; ENZYMOLOGY; GENETICS; HEART INFARCTION; KNOCKOUT MOUSE; METABOLISM; NEPHRECTOMY;

ANIMALS; DISEASE MODELS, ANIMAL; MALE; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; NEPHRECTOMY; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS;

EID: 84908327773     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.09.021     Document Type: Article

References (42)

1. White H.D., Chew D.P. Acute myocardial infarction. Lancet 2008, 372:570-584.
2. Antman E.M. ST-segment elevation myocardial infarction: pathology, pathophysiology, and clinical features. Braunwald's Heart Disease 2012, 1087-1110. Elsevier Saunders, Philadelphia. 9th ed. P. Libby, R.O. Bonow, D. Mann, D.P. Zipes (Eds.).
3. Antman E.M., Loscaldo J. ST-segment elevation myocardial infarction. Harrison's Principles of Internal Medicine 2012, 2012-2035. Mc Graw Hill Medical, New York. 18th ed. D.L. Longo, A.S. Fauci, D.L. Kasper, S.L. Hauser, J.L. Jameson, J. Loscalzo (Eds.).
4. Bredt D.S., Snyder S.H. Nitric oxide: a physiological messenger molecule. Annu Rev Biochem 1994, 63:175-195.
5. Ignarro L.J. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 1990, 30:535-560.
6. Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991, 43:109-142.
7. Murad F. What are the molecular mechanisms for the antiproliferative effects of nitric oxide and cGMP in vascular smooth muscle?. Circulation 1997, 95:1101-1103.
8. Shimokawa H. Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol 1999, 31:23-37.
9. Tsutsui M., Shimokawa H., Otsuji Y., Yanagihara N. Pathophysiological relevance of NO signaling in the cardiovascular system: novel insight from mice lacking all NO synthases. Pharmacol Ther 2010, 128:499-508.
10. Morishita T., Tsutsui M., Shimokawa H., Sabanai K., Tasaki H., Suda O., et al. Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms. Proc Natl Acad Sci U S A 2005, 102:10616-10621.
11. Nakata S., Tsutsui M., Shimokawa H., Suda O., Morishita T., Shibata K., et al. Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms. Circulation 2008, 117:2211-2223.
12. Coresh J., Selvin E., Stevens L.A., Manzi J., Kusek J.W., Eggers P., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038-2047.
13. Lopez-Novoa J.M., Martinez-Salgado C., Rodriguez-Pena A.B., Lopez-Hernandez F.J. Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives. Pharmacol Ther 2010, 128:61-81.
14. Ninomiya T., Kiyohara Y., Kubo M., Tanizaki Y., Doi Y., Okubo K., et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int 2005, 68:228-236.
15. Ninomiya T., Kiyohara Y., Tokuda Y., Doi Y., Arima H., Harada A., et al. Impact of kidney disease and blood pressure on the development of cardiovascular disease: an overview from the Japan Arteriosclerosis Longitudinal Study. Circulation 2008, 118:2694-2701.
16. Shoji T., Abe T., Matsuo H., Egusa G., Yamasaki Y., Kashihara N., et al. Chronic kidney disease, dyslipidemia, and atherosclerosis. J Atheroscler Thromb 2012, 19:299-315.
17. Miyazaki-Anzai S., Levi M., Kratzer A., Ting T.C., Lewis L.B., Miyazaki M. Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease. Circ Res 2010, 106:1807-1817.
18. Pelletier C.C., Koppe L., Croze M.L., Kalbacher E., Vella R.E., Guebre-Egziabher F., et al. White adipose tissue overproduces the lipid-mobilizing factor zinc alpha2-glycoprotein in chronic kidney disease. Kidney Int 2013, 83:878-886.
19. Schober A., Knarren S., Lietz M., Lin E.A., Weber C. Crucial role of stromal cell-derived factor-1alpha in neointima formation after vascular injury in apolipoprotein E-deficient mice. Circulation 2003, 108:2491-2497.
20. Moreno Junior H., Nathan L.P., Metze K., Costa S.K., Antunes E., Hyslop S., et al. Non-specific inhibitors of nitric oxide synthase cause myocardial necrosis in the rat. Clin Exp Pharmacol Physiol 1997, 24:349-352.
21. Ono Y., Ono H., Matsuoka H., Fujimori T., Frohlich E.D. Apoptosis, coronary arterial remodeling, and myocardial infarction after nitric oxide inhibition in SHR. Hypertension 1999, 34:609-616.
22. Verhagen A.M., Hohbach J., Joles J.A., Braam B., Boer P., Koomans H.A., et al. Unchanged cardiac angiotensin II levels accompany losartan-sensitive cardiac injury due to nitric oxide synthase inhibition. Eur J Pharmacol 2000, 400:239-247.
23. Ikeda K., Nara Y., Tagami M., Yamori Y. Nitric oxide deficiency induces myocardial infarction in hypercholesterolaemic stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1997, 24:344-348.
24. Suda O., Tsutsui M., Morishita T., Tanimoto A., Horiuchi M., Tasaki H., et al. Long-term treatment with N(omega)-nitro-L-arginine methyl ester causes arteriosclerotic coronary lesions in endothelial nitric oxide synthase-deficient mice. Circulation 2002, 106:1729-1735.
25. Braun A., Trigatti B.L., Post M.J., Sato K., Simons M., Edelberg J.M., et al. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res 2002, 90:270-276.
26. Zhang S., Picard M.H., Vasile E., Zhu Y., Raffai R.L., Weisgraber K.H., et al. Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction, and premature death in scavenger receptor class B type I-deficient, hypomorphic apolipoprotein ER61 mice. Circulation 2005, 111:3457-3464.
27. Nakagawa-Toyama Y., Zhang S., Krieger M. Dietary manipulation and social isolation alter disease progression in a murine model of coronary heart disease. PLoS One 2012, 7:e47965.
28. Taddei S., Virdis A., Ghiadoni L., Magagna A., Favilla S., Pompella A., et al. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension 2001, 37:943-948.
29. Tsuji H., Venditti F.J., Manders E.S., Evans J.C., Larson M.G., Feldman C.L., et al. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation 1994, 90:878-883.
30. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol 2008, 294:F1-F9.
31. Schmidt R.J., Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 2000, 58:1261-1266.
32. Wever R., Boer P., Hijmering M., Stroes E., Verhaar M., Kastelein J., et al. Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 1999, 19:1168-1172.
33. Lu T.M., Chung M.Y., Lin C.C., Hsu C.P., Lin S.J. Asymmetric dimethylarginine and clinical outcomes in chronic kidney disease. Clin J Am Soc Nephrol 2011, 6:1566-1572.
34. Piatti P., Di Mario C., Monti L.D., Fragasso G., Sgura F., Caumo A., et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 2003, 108:2074-2081.
35. Cooke J.P. ADMA: its role in vascular disease. Vasc Med 2005, 10(Suppl. 1):S11-S17.
36. Cook S. Coronary artery disease, nitric oxide and oxidative stress: the "Yin-Yang" effect, a Chinese concept for a worldwide pandemic. Swiss Med Wkly 2006, 136:103-113.
37. Shamseddin M.K., Parfrey P.S. Sudden cardiac death in chronic kidney disease: epidemiology and prevention. Nat Rev Nephrol 2011, 7:145-154.
38. Sata M., Saiura A., Kunisato A., Tojo A., Okada S., Tokuhisa T., et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002, 8:403-409.
39. Shimizu K., Sugiyama S., Aikawa M., Fukumoto Y., Rabkin E., Libby P., et al. Host bone-marrow cells are a source of donor intimal smooth- muscle-like cells in murine aortic transplant arteriopathy. Nat Med 2001, 7:738-741.
40. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004, 10:858-864.
41. Zhang L.N., Wilson D.W., da Cunha V., Sullivan M.E., Vergona R., Rutledge J.C., et al. Endothelial NO synthase deficiency promotes smooth muscle progenitor cells in association with upregulation of stromal cell-derived factor-1alpha in a mouse model of carotid artery ligation. Arterioscler Thromb Vasc Biol 2006, 26:765-772.
42. Mason R.P., Walter M.F., Trumbore M.W., Olmstead E.G., Mason P.E. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 1999, 31:275-281.